From Nalty to “Nalts”: The Transformation of a Pharma Marketing Director into a “Viral...
While Kevin Nalty worked during the day as Con-sumer Product Director at Merck, where he marketed Propecia, at night and on weekends he was making comedic videos for YouTube -- a few of which were critical of drug ads, marketing, and medical conditions. Read this interesting story and learn how not to get fired doing new media marketing.
The Empowered Patient: What It Means for Pharma Marketers
This article presents a case for the drug industry to adopt a patient-centric model in which pharma companies can develop unique expertise in decoding the behavior, needs, motivations of empowered patients and then use this knowledge as the basis for helping healthcare professionals and payers to put into place programs that achieve better patient outcomes.
Pharmaguy’s Twitter Followers
No matter what people say, your Twitter strategy must include building a large and qualified Twitter following. This article summarizes the findings of a survey of over 400 of @pharmaguy's followers. The results will give you a better idea why people who are interested in the pharmaceutical industry use Twitter and what they expect to get out of it.
Pharma Marketing News Vol. 8, #9
Welcome to the October 2009 issue of Pharma Marketing News.
Pharma Marketing News Vol. 8, #1
Welcome to the January 2009 issue of Pharma Marketing News.
Developing Guidelines for Pharma’s Use of the Internet & Social Media: Whatever! A Call...
Shouldn't we make sure that when it comes time for the FDA to actually create a guidance document on social media that it does it with input from ALL stakeholders? Survey results.
New Privacy Rules in Economic Stimulus Law: Will They Restrict Certain Pharmaceutical Marketing Practices?
This article reviews the medical privacy restrictions included in the American Recovery and Reinvestment Act, which President Obama signed into law on Feb. 17, 2009, and discusses the impact these restrictions might have on pharmaceutical marketing.
Pharma Marketing News Vol. 8, #9
Welcome to the October 2009 issue of Pharma Marketing News.
How Should Pharma Engage in Social Networks?: Thoughts on Best Practices
Each pharmaceutical company should have its own guidelines for best practices in the social media space. To assist in that discussion, Pharma Marketing News hosted a survey to explores issue relating to pharma advertising and engagement in social networks. This article summarizes the results of that survey.
Social Media Adverse Event Reporting Safe Harbors: It’s Time for FDA to Open Up...
This article presents ideas for regulatory 'safe harbors' under which pharmaceutical companies would be relieved of the responsibility of monitoring social media for adverse events. Includes a detailed summary of responses to the survey 'FDA Regulation of Drug & Device Promotion via the Internet & Social Media' regarding social media adverse event monitoring, processing, challenges, and uncertainties.
